Including non-concurrent control patients in the analysis of platform trials: is it worth it? (2020)

First Author: Lee K

Attributed to: Developing efficient perpetual platform trials to study multiple treatments and multiple biomarkers funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.71800

Publication URI: https://www.repository.cam.ac.uk/handle/1810/324346

Type: Other